Additional Chemotherapy for EGFRm Patients With the Continued Presence of

Status Recruiting

Clinical Trial Summary

PACE is a prospective multicenter single-arm investigator-initiated phase II trial that examines the value of a treatment escalation strategy by the addition of platinum-based doublet chemotherapy to osimertinib in patients with treatment-naïve NSCLC harboring L858R or del19 EGFR mutation who are suspected to have poor response upon single-agent TKI treatment.

Clinical Trial Description

Hypothesize, that in patients with on-label osimertinib 1st-line treatment of stage IIIB or IV NSCLC, a biomarker-driven escalation of osimertinib therapy with a platinum-based chemotherapy regimen will effectively enhance PFS and subsequently OS. Lack of EGFRm clearance after an osimertinib treatment period of 3 weeks as assessed by liquid biopsy will be used to predict sub-optimal response. In these patients, treatment will be escalated after approx. 7 weeks of on-label osimertinib monotherapy by adding up to 4 cycles of a combination regimen of pemetrexed and cisplatin or carboplatin. Patients with complete EGFR plasma clearance will continue to receive standard of care osimertinib and will not be eligible for the study. Primary outcome measure will be PFS, which will be compared to historical data on TKI monotherapy from persistent EGFR shedder from the FLAURA trial. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05281406
Study type	Interventional
Source	Goethe University
Contact	Martin Sebastian, MD
Phone	+49(0)69 6301
Email	martin.sebastian@kgu.de
Status	Recruiting
Phase	Phase 2
Start date	November 12, 2021
Completion date	November 2026

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05543330` - A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC	Phase 1/Phase 2
Recruiting	`NCT04106180` - SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC	Phase 2
Recruiting	`NCT05215548` - Primary Tumor Resection With EGFR TKI for Stage IV NSCLC	Phase 2
Recruiting	`NCT04042558` - A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies	Phase 2
Completed	`NCT04507217` - Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC	Phase 2
Recruiting	`NCT04467801` - Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy	Phase 2
Active, not recruiting	`NCT04027647` - Phase 2 Study of Dacomitinib in NSCLC	Phase 2
Recruiting	`NCT04768491` - Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC
Not yet recruiting	`NCT04492969` - Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
Recruiting	`NCT04116918` - Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC
Terminated	`NCT03411473` - Study of AGEN1884 With Pembrolizumab in 1L NSCLC	Phase 2
Recruiting	`NCT03564197` - 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC	N/A
Not yet recruiting	`NCT06219317` - Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC	Phase 2
Not yet recruiting	`NCT04604470` - Trial-specific Patient Decision Aid (tPDA) of the ImmunoSABR Phase 2
Recruiting	`NCT05132218` - Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer
Not yet recruiting	`NCT04136535` - Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC	Phase 2
Completed	`NCT03184571` - Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC	Phase 2
Completed	`NCT06339554` - Alectinib-induced Endocrine Toxicity
Active, not recruiting	`NCT04549428` - Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC	Phase 2
Recruiting	`NCT03647956` - Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors	Phase 2

Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms